Patents by Inventor Xiaoye Song

Xiaoye Song has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250065508
    Abstract: A zero calibration method includes: adding, based on a first forward kinematics model of a robotic arm of a robot, zero deviations of each joint to form a second forward kinematics model, and simultaneously solving the second forward kinematics model and the first forward kinematics model to obtain an end deviation function; sending target end pose instructions to the robotic arm in a current zero point situation, and acquiring a spatial deviation of an actual position of an end; inputting position information of each joint angle and the spatial deviation, after each stop of motion of the end, into the end deviation function, and performing phase shifting to obtain an objective optimization function; and solving the objective optimization function to obtain a zero deviation value.
    Type: Application
    Filed: November 12, 2024
    Publication date: February 27, 2025
    Inventors: Yang Wang, Hui Wu, Xiaoming Mai, Xiaoye Zhang, Peixin Li, Guoying Lin, Hao Wu, Jinghui Song, Qi Zeng, Ximeng Zhu, Qijiang Su, Junjie Guo, Ziyang Li, Jin Tan
  • Publication number: 20210163457
    Abstract: The present invention relates to canagliflozin Monohydrate and its crystalline forms. Compared to the prior art, canagliflozin Monohydrate and its crystalline forms have higher stability in water or aqueous system, is more suitable for wet granulation processes or suspension preparations and have good storage stability. The present invention also relates to preparation methods of canagliflozin Monohydrate and its crystalline forms, pharmaceutical compositions thereof and uses thereof in preparation of drugs for treating diseases such as diabetes, diabetes complications, obesity and so on.
    Type: Application
    Filed: February 10, 2021
    Publication date: June 3, 2021
    Applicant: Hangzhou Solipharma Co., Ltd.
    Inventors: Xiaoxia Sheng, Xiaohong Sheng, Kun Zhao, Xiaoye Song
  • Patent number: 10954223
    Abstract: The present invention relates to canagliflozin Monohydrate and its crystalline forms, which as compared to the prior art, have higher stability in water or aqueous system, are more suitable for wet granulation processes or suspension preparations and have good storage stability; the present invention also relates to preparation methods of canagliflozin Monohydrate and its crystalline forms, pharmaceutical compositions thereof and uses thereof in preparation of drugs for treating diseases such as diabetes, diabetes complications, obesity and so on.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: March 23, 2021
    Assignee: Hangzhou SoliPharma Co., Ltd.
    Inventors: Xiaoxia Sheng, Xiaohong Sheng, Kun Zhao, Xiaoye Song
  • Publication number: 20190315727
    Abstract: The present invention relates to canagliflozin Monohydrate and its crystalline forms, which as compared to the prior art, have higher stability in water or aqueous system, are more suitable for wet granulation processes or suspension preparations and have good storage stability; the present invention also relates to preparation methods of canagliflozin Monohydrate and its crystalline forms, pharmaceutical compositions thereof and uses thereof in preparation of drugs for treating diseases such as diabetes, diabetes complications, obesity and so on.
    Type: Application
    Filed: January 8, 2019
    Publication date: October 17, 2019
    Applicant: Hangzhou Pushai Pharmaceutical Technology Co., Ltd.
    Inventors: Xiaoxia Sheng, Xiaohong SHENG, Kun ZHAO, Xiaoye SONG
  • Patent number: 10174010
    Abstract: The present invention relates to canagliflozin Monohydrate and its crystalline forms, which as compared to the prior art, have higher stability in water or aqueous system, are more suitable for wet granulation processes or suspension preparations and have good storage stability; the present invention also relates to preparation methods of canagliflozin Monohydrate and its crystalline forms, pharmaceutical compositions thereof and uses thereof in preparation of drugs for treating diseases such as diabetes, diabetes complications, obesity and so on.
    Type: Grant
    Filed: July 4, 2014
    Date of Patent: January 8, 2019
    Assignee: HANGZHOU PUSHAI PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Xiaoxia Sheng, Xiaohong Sheng, Kun Zhao, Xiaoye Song
  • Publication number: 20170145000
    Abstract: The present invention relates to canagliflozin Monohydrate and its crystalline forms. Compared to the prior art, canagliflozin Monohydrate and its crystalline forms have higher stability in water or aqueous system, is more suitable for wet granulation processes or suspension preparations and have good storage stability. The present invention also relates to preparation methods of canagliflozin Monohydrate and its crystalline forms, pharmaceutical compositions thereof and uses thereof in preparation of drugs for treating diseases such as diabetes, diabetes complications, obesity and so on.
    Type: Application
    Filed: July 4, 2014
    Publication date: May 25, 2017
    Applicant: Hangzhou Pushai Pharmaceutical Technology Co., Ltd.
    Inventors: Xiaoxia SHENG, Xiaohong SHENG, Kun ZHAO, Xiaoye SONG
  • Patent number: 9562024
    Abstract: The present invention relates to the novel vortioxetine salts, solvates and crystalline forms thereof, specifically, vortioxetine hemihydrobromide and a crystalline form thereof, and isopropanol solvate of vortioxetine hydrobromide and a crystalline form thereof. Compared to the known vortioxetine hydrobromide, the vortioxetine salts, solvates and crystalline forms of the present invention have improved features in stability, hygroscopicity and purity. The present invention also relates to preparation methods of the vortioxetine salts, solvates and crystalline forms, pharmaceutical compositions thereof and their uses in the manufacture of antidepressant drugs.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: February 7, 2017
    Assignee: HANGZHOU PUSHAI PHARMACEUTICAL TECHNOLOGY CO., LTD
    Inventors: Xiaoye Song, Xiaoxia Sheng, Xiaohong Sheng
  • Publication number: 20160214950
    Abstract: The present invention relates to the novel vortioxetine salts, solvates and crystalline forms thereof, specifically, vortioxetine hemihydrobromide and a crystalline form thereof, and isopropanol solvate of vortioxetine hydrobromide and a crystalline form thereof. Compared to the known vortioxetine hydrobromide, the vortioxetine salts, solvates and crystalline forms of the present invention have improved features in stability, hygroscopicity and purity. The present invention also relates to preparation methods of the vortioxetine salts, solvates and crystalline forms, pharmaceutical compositions thereof and their uses in the manufacture of antidepressant drugs.
    Type: Application
    Filed: February 19, 2016
    Publication date: July 28, 2016
    Inventors: Xiaoye Song, Xiaoxia Sheng, Xiaohong Sheng
  • Publication number: 20160200698
    Abstract: The present invention relates to the novel vortioxetine salts, solvates and crystalline forms thereof, specifically, vortioxetine hemihydrobromide and a crystalline form thereof, and isopropanol solvate of vortioxetine hydrobromide and a crystalline form thereof. Compared to the known vortioxetine hydrobromide, the vortioxetine salts, solvates and crystalline forms of the present invention have improved features in stability, hygroscopicity and purity. The present invention also relates to preparation methods of the vortioxetine salts, solvates and crystalline forms, pharmaceutical compositions thereof and their uses in the manufacture of antidepressant drugs.
    Type: Application
    Filed: June 6, 2014
    Publication date: July 14, 2016
    Inventors: Xiaoye Song, Xiaoxia Sheng, Xiaohong Sheng